The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

Press release from PR Newswire

Watson Receives FTC Clearance for Actavis Acquisition

Monday, October 15, 2012

Watson Receives FTC Clearance for Actavis Acquisition17:17 EDT Monday, October 15, 2012PARSIPPANY, N.J., Oct. 15, 2012 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced that the Federal Trade Commission (FTC) has voted to approve Watson's acquisition of the Actavis group of companies.  The unanimous vote in support of the transaction follows Watson's agreement to a proposed consent order, pursuant to which Watson has agreed to divest certain products as a condition to obtaining FTC approval.  The parties have now obtained all regulatory approvals required to close the transaction.  Accordingly, the parties expect to consummate the acquisition in late October or early November.Under the terms of the consent order with the FTC, Watson and Actavis have agreed to divest a number of marketed and pipeline products to Par Pharmaceutical Companies, Inc. and Sandoz. Subject to the consummation of the transaction between Watson and Actavis, Par will acquire the following products:Watson's Morphine Sulfate Extended Release Capsules Actavis' Nifedipine Extended Release Tablets Actavis' Metoclopramide Hydrochloride Tablets Actavis' Fentanyl Transdermal Film Actavis' Diltiazem Hydrochloride Extended Release Capsules  Watson's pending application for Adapalene/Benzoyl Peroxide Gel Watson's pending application for Oxymorphone hydrochloride ER Tablets Watson's pending application for Amphetamine Salts ER Tablets Actavis' pending application for Rivastigmine Patch Actavis' pending application for Glipizide Extended Release Tablets Actavis' pending application for Varenicline Tartrate Tablets Actavis' pending application for Oxycodone Hydrochloride Extended Release Tablets Actavis' pending application for Ursodiol Tablets  Actavis' development stage Methylphenidate Hydrochloride Extended Release TabletsSubject to the consummation of the transaction between Watson and Actavis, Sandoz will acquire the following products:Actavis' Bupropion Hydrochloride 150 mg. Extended Release Tablets Actavis' Lorazepam Tablets Actavis' Diltiazem Hydrochloride Extended Release Capsules Watson's pending application for Dextromethorphan Hydrobromide /Quinidine Sulfate About Watson Pharmaceuticals, Inc.Watson Pharmaceuticals, Inc. is an integrated global specialty pharmaceutical company. The Company is engaged in the development, manufacturing, marketing and distribution of generic pharmaceuticals and specialized branded pharmaceutical products focused on Urology and Women's Health. The Company is also developing biosimilar products in Women's Health and Oncology.  Additionally, Watson distributes generic and branded pharmaceuticals through its Anda, Inc. distribution business.  Watson has operations in many of the world's established and growing international markets. For press release and other company information, visit Watson Pharmaceuticals' Web site at http://www.watson.com. Forward-Looking StatementAny statements contained in this press release that refer to future events or other non-historical facts are forward-looking statements that reflect Watson's current perspective of existing trends and information as of the date of this release. Except as expressly required by law, Watson disclaims any intent or obligation to update these forward-looking statements. Actual results may differ materially from Watson's current expectations depending upon a number of factors affecting Watson's business. These factors include, among others, the uncertainty associated with the successful and timely consummation and subsequent integration of the Actavis acquisition and the ability to recognize the anticipated synergies and benefits of the Actavis acquisition; the receipt of required final regulatory approvals for the Actavis acquisition transaction, including the approval of the FTC, necessary to complete the acquisition; risks of fluctuations in foreign currency exchange rates; and other risks and uncertainties detailed in Watson's periodic public filings with the Securities and Exchange Commission, including but not limited to Watson's Quarterly Report on Form 10-Q for the period ended June 30, 2012 and Watson's Annual Report on Form 10-K for the period ended December 31, 2011.All trademarks are the property of their respective owners. CONTACTS: Investors: Lisa DeFrancesco(862) 261-7152Media:Charlie Mayr(862) 261-8030(Logo: http://photos.prnewswire.com/prnh/20100121/LA41294LOGO )SOURCE Watson Pharmaceuticals, Inc.